These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

99 related articles for article (PubMed ID: 2303284)

  • 21. [An echocardiographic study of the left ventricular functional indices in pediatric patients on hemodialysis and in treatment with recombinant human erythropoietin (r-HuEPO)].
    Seracini D; Pollini I; Lavoratti GC; Pela I; Materassi M; Danti D; De Simone L; Favilli S; Manetti A
    Pediatr Med Chir; 1994; 16(4):389-92. PubMed ID: 7816703
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Long-term effects of recombinant human erythropoietin on macro- and microcirculation in chronic hemodialysis patients.
    Wirtz JJ; Leunissen KM; van Kuijk W; Cheriex EC; Slaaf DW; Reneman RS; van Hooff JP
    Blood Purif; 1993; 11(4):237-47. PubMed ID: 8297565
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Therapy with recombinant human erythropoietin reduces cardiac size and improves heart function in chronic hemodialysis patients.
    Löw-Friedrich I; Grützmacher P; März W; Bergmann M; Schoeppe W
    Am J Nephrol; 1991; 11(1):54-60. PubMed ID: 1828650
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Recombinant erythropoietin (Epogen) improves cardiac exercise performance in children with end-stage renal disease.
    Martin GR; Ongkingo JR; Turner ME; Skurow ES; Ruley EJ
    Pediatr Nephrol; 1993 Jun; 7(3):276-80. PubMed ID: 8518098
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Influence of long-term amelioration of anemia and blood pressure control on left ventricular hypertrophy in hemodialyzed patients.
    Zehnder C; Zuber M; Sulzer M; Meyer B; Straumann E; Jenzer HR; Blumberg A
    Nephron; 1992; 61(1):21-5. PubMed ID: 1388250
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Hemodynamics of patients with renal failure treated with recombinant human erythropoietin.
    Verbeelen D; Bossuyt A; Smitz J; Herman A; Dratwa M; Jonckheer MH
    Clin Nephrol; 1989 Jan; 31(1):6-11. PubMed ID: 2914412
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Hemodynamic and hormonal changes during erythropoietin therapy in hemodialysis patients.
    Lebel M; Kingma I; Grose JH; Langlois S
    J Am Soc Nephrol; 1998 Jan; 9(1):97-104. PubMed ID: 9440093
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Usefulness of long axis M-mode echocardiographic measurements for optimum dialysis in patients on maintenance hemodialysis: comparison with changes in plasma levels of atrial natriuretic peptide and brain natriuretic peptide.
    Sugihara K; Fujimoto S; Motomiya Y; Hashimoto T; Nakamura S; Dohi K
    Clin Nephrol; 2001 Aug; 56(2):140-9. PubMed ID: 11522091
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Renal function during erythropoietin therapy for anemia in predialysis chronic renal failure patients.
    Abraham PA; Opsahl JA; Rachael KM; Asinger R; Halstenson CE
    Am J Nephrol; 1990; 10(2):128-36. PubMed ID: 2349956
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Hemodynamic mechanism of the elevation in blood pressure following the improvement of anemia with recombinant human erythropoietin.
    Kamata K; Marumo F; Onoyama K
    Jpn Circ J; 1991 Jul; 55(7):649-56. PubMed ID: 1880896
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effect of erythropoietin on cardiovascular prognosis parameters in hemodialysis patients.
    Frank H; Heusser K; Höffken B; Huber P; Schmieder RE; Schobel HP
    Kidney Int; 2004 Aug; 66(2):832-40. PubMed ID: 15253740
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Recurrence of left ventricular hypertrophy following cessation of erythropoietin therapy.
    Sikole A; Polenakovic M; Spiroska V; Polenakovic B; Klinkmann H; Scigalla P
    Artif Organs; 2002 Feb; 26(2):98-102. PubMed ID: 11879236
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Changes in left ventricular mass and filling after renal transplantation are related to changes in blood pressure: an echocardiographic and pulsed Doppler study.
    Peteiro J; Alvarez N; Calviño R; Penas M; Ribera F; Castro Beiras A
    Cardiology; 1994; 85(5):273-83. PubMed ID: 7850816
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Morphologic and functional changes of left ventricle in dialyzed patients after treatment with recombinant human erythropoietin (r-HuEPO).
    Jeren-Struji'c B; Raos V; Jeren T; Horvatin-Godler S
    Angiology; 2000 Feb; 51(2):131-9. PubMed ID: 10701721
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Hemodynamic effects of partial correction of chronic anemia by recombinant human erythropoietin in patients on dialysis.
    Mayer G; Cada EM; Watzinger U; Barnas U; Graf H
    Am J Kidney Dis; 1991 Mar; 17(3):286-9. PubMed ID: 1996570
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Erythropoietin treatment does not compromise cardiovascular function in chronic renal failure.
    Haedersdal C; Mehlsen J; Stenver D; Nielsen B; Jeppesen L; Winther K
    Angiology; 1994 Mar; 45(3):231-4. PubMed ID: 8129205
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pressor effect of recombinant human erythropoietin: results of ambulatory blood pressure monitoring and home blood pressure measurements.
    Imai Y; Sekino H; Fujikura Y; Munakata M; Minami N; Hashimoto J; Sakuma H; Watanabe N; Misawa S; Nishiyama A
    Clin Exp Hypertens; 1995 Apr; 17(3):485-506. PubMed ID: 7613524
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Endogenous erythropoietin correlates with blood pressure in essential hypertension.
    Schmieder RE; Langenfeld MR; Hilgers KF
    Am J Kidney Dis; 1997 Mar; 29(3):376-82. PubMed ID: 9041213
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Hemodynamic and cardiac effects of erythropoietin in patients on regular dialysis.
    Pascual J; Teruel JL; Marcén R; Liaño F; Moya JL; Jiménez M; Ortuño J
    Int J Artif Organs; 1992 Jun; 15(6):349-53. PubMed ID: 1639526
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The cardiovascular and hemodynamic effects of erythropoietin in chronic renal failure.
    Singh NP; Chandrashekhar ; Nair M; Anuradha S; Kohli R; Agarwal SK
    J Assoc Physicians India; 2000 Mar; 48(3):301-6. PubMed ID: 11229114
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.